{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T18:04:54Z","timestamp":1770833094154,"version":"3.50.1"},"reference-count":133,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,5,16]],"date-time":"2019-05-16T00:00:00Z","timestamp":1557964800000},"content-version":"vor","delay-in-days":45,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001858","name":"VINNOVA","doi-asserted-by":"crossref","award":["2018-00177"],"award-info":[{"award-number":["2018-00177"]}],"id":[{"id":"10.13039\/501100001858","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004348","name":"Stockholms L?ns Landsting","doi-asserted-by":"publisher","award":["20180860"],"award-info":[{"award-number":["20180860"]}],"id":[{"id":"10.13039\/501100004348","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004348","name":"Stockholms L?ns Landsting","doi-asserted-by":"publisher","award":["20180860"],"award-info":[{"award-number":["20180860"]}],"id":[{"id":"10.13039\/501100004348","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004348","name":"Stockholms L?ns Landsting","doi-asserted-by":"publisher","award":["LS2016-1448"],"award-info":[{"award-number":["LS2016-1448"]}],"id":[{"id":"10.13039\/501100004348","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr?det","doi-asserted-by":"publisher","award":["2017-02131"],"award-info":[{"award-number":["2017-02131"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["CAN 17 0472"],"award-info":[{"award-number":["CAN 17 0472"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s13311-019-00712-9","type":"journal-article","created":{"date-parts":[[2019,5,16]],"date-time":"2019-05-16T13:12:09Z","timestamp":1558012329000},"page":"248-262","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Targeted Oligonucleotides for Treating Neurodegenerative Tandem Repeat Diseases"],"prefix":"10.1016","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8327-846X","authenticated-orcid":false,"given":"Rula","family":"Zain","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1907-3392","authenticated-orcid":false,"given":"C. I. Edvard","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5058","key":"10.1007\/s13311-019-00712-9_bib1","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1126\/science.256.5058.784","article-title":"Triplet repeat mutations in human disease","volume":"256","author":"Caskey","year":"1992","journal-title":"Science."},{"issue":"7147","key":"10.1007\/s13311-019-00712-9_bib2","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/nature05977","article-title":"Expandable DNA repeats and human disease","volume":"447","author":"Mirkin","year":"2007","journal-title":"Nature"},{"key":"10.1007\/s13311-019-00712-9_bib3","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1146\/annurev-biochem-060614-034010","article-title":"DNA triplet repeat expansion and mismatch repair","volume":"84","author":"Iyer","year":"2015","journal-title":"Annu Rev Biochem"},{"issue":"5","key":"10.1007\/s13311-019-00712-9_bib4","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/nrg.2017.115","article-title":"Tandem repeats mediating genetic plasticity in health and disease","volume":"19","author":"Hannan","year":"2018","journal-title":"Nat Rev Genet"},{"issue":"6","key":"10.1007\/s13311-019-00712-9_bib5","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.tig.2018.02.005","article-title":"Cis- and Trans-Modifiers of Repeat Expansions: Blending Model Systems with Human Genetics","volume":"34","author":"McGinty","year":"2018","journal-title":"Trends Genet"},{"key":"10.1007\/s13311-019-00712-9_bib6","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1146\/annurev-pharmtox-010818-021050","article-title":"Therapeutic Oligonucleotides: State of the Art","volume":"59","author":"Smith","year":"2019","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"10","key":"10.1007\/s13311-019-00712-9_bib7","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/nrd.2018.133","article-title":"Therapeutic approaches to Huntington disease: from the bench to the clinic","volume":"17","author":"Caron","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"10.1007\/s13311-019-00712-9_bib8","doi-asserted-by":"crossref","DOI":"10.1177\/1756286418776932","article-title":"Antisense oligonucleotides in neurological disorders","volume":"11","author":"Wurster","year":"2018","journal-title":"Ther Adv Neurol Disord"},{"issue":"10","key":"10.1007\/s13311-019-00712-9_bib9","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/nrn.2017.92","article-title":"Polyglutamine spinocerebellar ataxias - from genes to potential treatments","volume":"18","author":"Paulson","year":"2017","journal-title":"Nat Rev Neurosci"},{"issue":"5254","key":"10.1007\/s13311-019-00712-9_bib10","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1126\/science.271.5254.1423","article-title":"Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion","volume":"271","author":"Campuzano","year":"1996","journal-title":"Science"},{"issue":"9","key":"10.1007\/s13311-019-00712-9_bib11","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1080\/14737175.2017.1356721","article-title":"Pharmacological therapeutics in Friedreich ataxia: the present state","volume":"17","author":"Strawser","year":"2017","journal-title":"Expert Rev Neurother"},{"issue":"5","key":"10.1007\/s13311-019-00712-9_bib12","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/0092-8674(91)90397-H","article-title":"Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome","volume":"65","author":"Verkerk","year":"1991","journal-title":"Cell"},{"issue":"4","key":"10.1007\/s13311-019-00712-9_bib13","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/nrd.2017.221","article-title":"Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome","volume":"17","author":"Berry-Kravis","year":"2018","journal-title":"Nat Rev Drug Discov"},{"issue":"5009","key":"10.1007\/s13311-019-00712-9_bib14","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1126\/science.252.5009.1097","article-title":"Instability of a 550-base pair DNA segment and abnormal methylation in fragile X syndrome","volume":"252","author":"Oberle","year":"1991","journal-title":"Science"},{"issue":"4","key":"10.1007\/s13311-019-00712-9_bib15","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/0092-8674(91)90125-I","article-title":"Absence of expression of the FMR-1 gene in fragile X syndrome","volume":"66","author":"Pieretti","year":"1991","journal-title":"Cell"},{"key":"10.1007\/s13311-019-00712-9_bib16","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/B978-0-444-63233-3.00025-7","article-title":"Fragile X syndrome and fragile X-associated tremor ataxia syndrome","volume":"147","author":"Hall","year":"2018","journal-title":"Handb Clin Neurol"},{"key":"10.1007\/s13311-019-00712-9_bib17","doi-asserted-by":"crossref","first-page":"314","DOI":"10.3389\/fgene.2018.00314","article-title":"Timing of Expansion of Fragile X Premutation Alleles During Intergenerational Transmission in a Mouse Model of the Fragile X-Related Disorders","volume":"9","author":"Zhao","year":"2018","journal-title":"Front Genet"},{"issue":"10","key":"10.1007\/s13311-019-00712-9_bib18","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1038\/ejhg.2009.51","article-title":"Penetrance of FMR1 premutation associated pathologies in fragile X syndrome families","volume":"17","author":"Rodriguez-Revenga","year":"2009","journal-title":"Eur J Hum Genet"},{"issue":"2","key":"10.1007\/s13311-019-00712-9_bib19","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1089\/ard.1991.1.141","article-title":"Substrate specificity and kinetics of degradation of antisense oligonucleotides by a 3\u2032 exonuclease in plasma","volume":"1","author":"Eder","year":"1991","journal-title":"Antisense Res Dev"},{"issue":"5","key":"10.1007\/s13311-019-00712-9_bib20","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/S0026-895X(25)10208-3","article-title":"Biodistribution and metabolism of internally 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate","volume":"45","author":"Sands","year":"1994","journal-title":"Mol Pharmacol"},{"issue":"3","key":"10.1007\/s13311-019-00712-9_bib21","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nbt.3765","article-title":"The chemical evolution of oligonucleotide therapies of clinical utility","volume":"35","author":"Khvorova","year":"2017","journal-title":"Nat Biotechnol"},{"issue":"4","key":"10.1007\/s13311-019-00712-9_bib22","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1089\/108729000421475","article-title":"Heterocyclic modifications of oligonucleotides and antisense technology","volume":"10","author":"Herdewijn","year":"2000","journal-title":"Antisense Nucleic Acid Drug Dev"},{"issue":"8","key":"10.1007\/s13311-019-00712-9_bib23","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.chembiol.2012.07.011","article-title":"Designing chemically modified oligonucleotides for targeted gene silencing","volume":"19","author":"Deleavey","year":"2012","journal-title":"Chem Biol"},{"issue":"2","key":"10.1007\/s13311-019-00712-9_bib24","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA","volume":"23","author":"Kariko","year":"2005","journal-title":"Immunity"},{"issue":"11","key":"10.1007\/s13311-019-00712-9_bib25","doi-asserted-by":"crossref","first-page":"4403","DOI":"10.1093\/nar\/15.11.4403","article-title":"Site-directed cleavage of RNA","volume":"15","author":"Shibahara","year":"1987","journal-title":"Nucleic Acids Res"},{"issue":"19","key":"10.1007\/s13311-019-00712-9_bib26","doi-asserted-by":"crossref","first-page":"14514","DOI":"10.1016\/S0021-9258(19)85268-7","article-title":"Evaluation of 2\u2032-modified oligonucleotides containing 2\u2032-deoxy gaps as antisense inhibitors of gene expression","volume":"268","author":"Monia","year":"1993","journal-title":"J Biol Chem"},{"issue":"16","key":"10.1007\/s13311-019-00712-9_bib27","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1016\/S0960-894X(98)00366-7","article-title":"The first analogues of LNA (locked nucleic acids): phosphorothioate-LNA and 2\u2032-thio-LNA","volume":"8","author":"Kumar","year":"1998","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1007\/s13311-019-00712-9_bib28","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1016\/S0040-4020(98)00094-5","article-title":"Synthesis of the adenine, cytosine, guanine, 5-methylcytosine, thymine and uracil bicyclonucleoside monomers, oligomerisation, and unprecedented nucleic acid recognition","volume":"54","author":"Koshkin","year":"1998","journal-title":"Tetrahedon"},{"key":"10.1007\/s13311-019-00712-9_bib29","doi-asserted-by":"crossref","first-page":"8735","DOI":"10.1016\/S0040-4039(97)10322-7","article-title":"Novel bicyclic nucleosides having a fixed C3'-endo sugar puckering","volume":"54","author":"Obika","year":"1997","journal-title":"Tetrahedon Letter"},{"issue":"1","key":"10.1007\/s13311-019-00712-9_bib30","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1021\/jm801294h","article-title":"Short antisense oligonucleotides with novel 2\u2032-4\u2032 conformationaly restricted nucleoside analogues show improved potency without increased toxicity in animals","volume":"52","author":"Seth","year":"2009","journal-title":"J Med Chem"},{"issue":"1","key":"10.1007\/s13311-019-00712-9_bib31","doi-asserted-by":"crossref","first-page":"11043","DOI":"10.1038\/s41598-017-09147-8","article-title":"LNA effects on DNA binding and conformation: from single strand to duplex and triplex structures","volume":"7","author":"Pabon-Martinez","year":"2017","journal-title":"Sci Rep"},{"issue":"5","key":"10.1007\/s13311-019-00712-9_bib32","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1021\/jo902560f","article-title":"Synthesis and biophysical evaluation of 2\u2032,4\u2032-constrained 2'O-methoxyethyl and 2\u2032,4\u2032-constrained 2'O-ethyl nucleic acid analogues","volume":"75","author":"Seth","year":"2010","journal-title":"J Organomet Chem"},{"issue":"2","key":"10.1007\/s13311-019-00712-9_bib33","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1089\/oli.1.2000.10.117","article-title":"Phosphorothioate oligodeoxynucleotides: what is their origin and what is unique about them?","volume":"10","author":"Eckstein","year":"2000","journal-title":"Antisense Nucleic Acid Drug Dev"},{"issue":"17","key":"10.1007\/s13311-019-00712-9_bib34","doi-asserted-by":"crossref","first-page":"7595","DOI":"10.1073\/pnas.88.17.7595","article-title":"Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice","volume":"88","author":"Agrawal","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1007\/s13311-019-00712-9_bib35","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1089\/nat.2015.0593","article-title":"Considerations for the Characterization and Interpretation of Results Related to Alternative Complement Activation in Monkeys Associated with Oligonucleotide-Based Therapeutics","volume":"26","author":"Henry","year":"2016","journal-title":"Nucleic Acid Ther"},{"issue":"3","key":"10.1007\/s13311-019-00712-9_bib36","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1089\/nat.2016.0650","article-title":"The Effects of 2'-O-Methoxyethyl Containing Antisense Oligonucleotides on Platelets in Human Clinical Trials","volume":"27","author":"Crooke","year":"2017","journal-title":"Nucleic Acid Ther"},{"issue":"2","key":"10.1007\/s13311-019-00712-9_bib37","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1093\/toxsci\/kfy119","article-title":"Investigation into the Mechanism(s) That Leads to Platelet Decreases in Cynomolgus Monkeys During Administration of ISIS 104838, a 2'-MOE-Modified Antisense Oligonucleotide","volume":"164","author":"Narayanan","year":"2018","journal-title":"Toxicol Sci"},{"issue":"5","key":"10.1007\/s13311-019-00712-9_bib38","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1093\/nar\/gkv143","article-title":"Identification and characterization of intracellular proteins that bind oligonucleotides with phosphorothioate linkages","volume":"43","author":"Liang","year":"2015","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"10.1007\/s13311-019-00712-9_bib39","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1093\/nar\/25.4.776","article-title":"RNase H-independent antisense activity of oligonucleotide N3 \u2018\u2013> P5 \u2018 phosphoramidates","volume":"25","author":"Heidenreich","year":"1997","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"10.1007\/s13311-019-00712-9_bib40","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1093\/nar\/23.2.217","article-title":"Efficient pH-independent sequence-specific DNA binding by pseudoisocytosine-containing bis-PNA","volume":"23","author":"Egholm","year":"1995","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"10.1007\/s13311-019-00712-9_bib41","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1089\/oli.1.1997.7.187","article-title":"Morpholino antisense oligomers: design, preparation, and properties","volume":"7","author":"Summerton","year":"1997","journal-title":"Antisense Nucleic Acid Drug Dev"},{"issue":"11","key":"10.1007\/s13311-019-00712-9_bib42","doi-asserted-by":"crossref","first-page":"e0165788","DOI":"10.1371\/journal.pone.0165788","article-title":"Disruption of Higher Order DNA Structures in Friedreich's Ataxia (GAA)n Repeats by PNA or LNA Targeting","volume":"11","author":"Bergquist","year":"2016","journal-title":"PLoS One"},{"issue":"2","key":"10.1007\/s13311-019-00712-9_bib43","first-page":"184","article-title":"Sequence-selective targeting of duplex DNA by peptide nucleic acids","volume":"12","author":"Nielsen","year":"2010","journal-title":"Curr Opin Mol Ther"},{"issue":"5","key":"10.1007\/s13311-019-00712-9_bib44","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1093\/nar\/gkt007","article-title":"Development of bis-locked nucleic acid (bisLNA) oligonucleotides for efficient invasion of supercoiled duplex DNA","volume":"41","author":"Moreno","year":"2013","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"10.1007\/s13311-019-00712-9_bib45","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1093\/nar\/gkw021","article-title":"Next-generation bis-locked nucleic acids with stacking linker and 2\u2032-glycylamino-LNA show enhanced DNA invasion into supercoiled duplexes","volume":"44","author":"Geny","year":"2016","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"10.1007\/s13311-019-00712-9_bib46","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1073\/pnas.75.1.280","article-title":"Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide","volume":"75","author":"Zamecnik","year":"1978","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1007\/s13311-019-00712-9_bib47","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1073\/pnas.75.1.285","article-title":"Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide","volume":"75","author":"Stephenson","year":"1978","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"10.1007\/s13311-019-00712-9_bib48","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1089\/hum.2015.070","article-title":"Oligonucleotide Therapies: The Past and the Present","volume":"26","author":"Lundin","year":"2015","journal-title":"Hum Gene Ther"},{"issue":"5","key":"10.1007\/s13311-019-00712-9_bib49","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/nbt.1539","article-title":"Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs","volume":"27","author":"Hu","year":"2009","journal-title":"Nat Biotechnol"},{"issue":"5222","key":"10.1007\/s13311-019-00712-9_bib50","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1126\/science.7618107","article-title":"Inactivation of the mouse Huntington's disease gene homolog Hdh","volume":"269","author":"Duyao","year":"1995","journal-title":"Science"},{"issue":"5","key":"10.1007\/s13311-019-00712-9_bib51","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/0092-8674(95)90542-1","article-title":"Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes","volume":"81","author":"Nasir","year":"1995","journal-title":"Cell"},{"issue":"2","key":"10.1007\/s13311-019-00712-9_bib52","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/ng1095-155","article-title":"Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue","volume":"11","author":"Zeitlin","year":"1995","journal-title":"Nat Genet"},{"issue":"4","key":"10.1007\/s13311-019-00712-9_bib53","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/ng1297-404","article-title":"Huntingtin is required for neurogenesis and is not impaired by the Huntington's disease CAG expansion","volume":"17","author":"White","year":"1997","journal-title":"Nat Genet"},{"issue":"12","key":"10.1007\/s13311-019-00712-9_bib54","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1038\/mt.2011.219","article-title":"Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington's disease","volume":"19","author":"McBride","year":"2011","journal-title":"Mol Ther"},{"issue":"Pt 4","key":"10.1007\/s13311-019-00712-9_bib55","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1093\/brain\/awr333","article-title":"Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum","volume":"135","author":"Grondin","year":"2012","journal-title":"Brain"},{"issue":"8","key":"10.1007\/s13311-019-00712-9_bib56","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1242\/dev.125.8.1529","article-title":"Mouse mutant embryos lacking huntingtin are rescued from lethality by wild-type extraembryonic tissues","volume":"125","author":"Dragatsis","year":"1998","journal-title":"Development"},{"issue":"7","key":"10.1007\/s13311-019-00712-9_bib57","doi-asserted-by":"crossref","first-page":"e1006846","DOI":"10.1371\/journal.pgen.1006846","article-title":"Elimination of huntingtin in the adult mouse leads to progressive behavioral deficits, bilateral thalamic calcification, and altered brain iron homeostasis","volume":"13","author":"Dietrich","year":"2017","journal-title":"PLoS Genet"},{"issue":"Pt 12","key":"10.1007\/s13311-019-00712-9_bib58","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1093\/brain\/awv292","article-title":"Broad distribution of ataxin 1 silencing in rhesus cerebella for spinocerebellar ataxia type 1 therapy","volume":"138","author":"Keiser","year":"2015","journal-title":"Brain"},{"issue":"1","key":"10.1007\/s13311-019-00712-9_bib59","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1006\/exnr.1996.6400","article-title":"Antisense gene therapy for neurodegenerative disease?","volume":"144","author":"Haque","year":"1997","journal-title":"Exp Neurol"},{"issue":"3","key":"10.1007\/s13311-019-00712-9_bib60","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/1531-8249(199909)46:3<366::AID-ANA12>3.0.CO;2-D","article-title":"Sequence-specific cleavage of Huntingtin mRNA by catalytic DNA","volume":"46","author":"Yen","year":"1999","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1007\/s13311-019-00712-9_bib61","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1006\/mcne.2000.0872","article-title":"Inhibition of Huntington synthesis by antisense oligodeoxynucleotides","volume":"16","author":"Nellemann","year":"2000","journal-title":"Mol Cell Neurosci"},{"issue":"6","key":"10.1007\/s13311-019-00712-9_bib62","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.neuron.2012.05.009","article-title":"Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis","volume":"74","author":"Kordasiewicz","year":"2012","journal-title":"Neuron"},{"issue":"9","key":"10.1007\/s13311-019-00712-9_bib63","doi-asserted-by":"crossref","first-page":"e24308","DOI":"10.1371\/journal.pone.0024308","article-title":"Targeting several CAG expansion diseases by a single antisense oligonucleotide","volume":"6","author":"Evers","year":"2011","journal-title":"PLoS One"},{"issue":"7","key":"10.1007\/s13311-019-00712-9_bib64","doi-asserted-by":"crossref","first-page":"723","DOI":"10.3727\/096368908786516729","article-title":"Antisense RNA sequences modulating the ataxin-1 message: molecular model of gene therapy for spinocerebellar ataxia type 1, a dominant-acting unstable trinucleotide repeat disease","volume":"17","author":"Gao","year":"2008","journal-title":"Cell Transplant"},{"issue":"33","key":"10.1007\/s13311-019-00712-9_bib65","doi-asserted-by":"crossref","first-page":"13915","DOI":"10.1073\/pnas.0905780106","article-title":"Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy","volume":"106","author":"Mulders","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"21","key":"10.1007\/s13311-019-00712-9_bib66","doi-asserted-by":"crossref","first-page":"5985","DOI":"10.1093\/hmg\/ddv300","article-title":"Silencing neuronal mutant androgen receptor in a mouse model of spinal and bulbar muscular atrophy","volume":"24","author":"Sahashi","year":"2015","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-019-00712-9_bib67","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.omtn.2017.06.019","article-title":"Antisense Oligonucleotide-Mediated Removal of the Polyglutamine Repeat in Spinocerebellar Ataxia Type 3 Mice","volume":"8","author":"Toonen","year":"2017","journal-title":"Mol Ther Nucleic Acids"},{"issue":"3","key":"10.1007\/s13311-019-00712-9_bib68","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ajhg.2009.02.003","article-title":"CAG expansion in the Huntington disease gene is associated with a specific and targetable predisposing haplogroup","volume":"84","author":"Warby","year":"2009","journal-title":"Am J Hum Genet"},{"issue":"12","key":"10.1007\/s13311-019-00712-9_bib69","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1038\/mt.2014.153","article-title":"In vivo evaluation of candidate allele-specific mutant huntingtin gene silencing antisense oligonucleotides","volume":"22","author":"Southwell","year":"2014","journal-title":"Mol Ther"},{"key":"10.1007\/s13311-019-00712-9_bib70","doi-asserted-by":"crossref","unstructured":"Southwell AL, Kordasiewicz HB, Langbehn D, Skotte NH, Parsons MP, Villanueva EB, et al. Huntingtin suppression restores cognitive function in a mouse model of Huntington's disease. Sci Transl Med 2018;10(461).","DOI":"10.1126\/scitranslmed.aar3959"},{"issue":"21","key":"10.1007\/s13311-019-00712-9_bib71","doi-asserted-by":"crossref","first-page":"9634","DOI":"10.1093\/nar\/gkt725","article-title":"Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS","volume":"41","author":"Ostergaard","year":"2013","journal-title":"Nucleic Acids Res"},{"issue":"12","key":"10.1007\/s13311-019-00712-9_bib72","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1038\/mt.2011.201","article-title":"Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene \/ allele-specific silencing of mutant huntingtin","volume":"19","author":"Carroll","year":"2011","journal-title":"Mol Ther"},{"key":"10.1007\/s13311-019-00712-9_bib73","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1146\/annurev.pharmtox.010909.105654","article-title":"RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform","volume":"50","author":"Bennett","year":"2010","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"10","key":"10.1007\/s13311-019-00712-9_bib74","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1016\/j.celrep.2018.07.106","article-title":"Nuclear Localization of Huntingtin mRNA Is Specific to Cells of Neuronal Origin","volume":"24","author":"Didiot","year":"2018","journal-title":"Cell Rep"},{"issue":"8","key":"10.1007\/s13311-019-00712-9_bib75","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/nm1076","article-title":"RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia","volume":"10","author":"Xia","year":"2004","journal-title":"Nat Med"},{"key":"10.1007\/s13311-019-00712-9_bib76","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.nbd.2013.04.003","article-title":"RNAi or overexpression: alternative therapies for Spinocerebellar Ataxia Type 1","volume":"56","author":"Keiser","year":"2013","journal-title":"Neurobiol Dis"},{"issue":"12","key":"10.1007\/s13311-019-00712-9_bib77","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1093\/hmg\/ddq111","article-title":"Silencing ataxin-3 mitigates degeneration in a rat model of Machado-Joseph disease: no role for wild-type ataxin-3?","volume":"19","author":"Alves","year":"2010","journal-title":"Hum Mol Genet"},{"issue":"9","key":"10.1007\/s13311-019-00712-9_bib78","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.cub.2009.03.030","article-title":"Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients","volume":"19","author":"Pfister","year":"2009","journal-title":"Curr Biol"},{"issue":"10","key":"10.1007\/s13311-019-00712-9_bib79","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/gt.2017.71","article-title":"AAV5-miHTT gene therapy demonstrates suppression of mutant huntingtin aggregation and neuronal dysfunction in a rat model of Huntington's disease","volume":"24","author":"Miniarikova","year":"2017","journal-title":"Gene Ther"},{"issue":"9","key":"10.1007\/s13311-019-00712-9_bib80","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1016\/j.ymthe.2018.06.021","article-title":"AAV5-miHTT Gene Therapy Demonstrates Broad Distribution and Strong Human Mutant Huntingtin Lowering in a Huntington's Disease Minipig Model","volume":"26","author":"Evers","year":"2018","journal-title":"Mol Ther"},{"key":"10.1007\/s13311-019-00712-9_bib81","doi-asserted-by":"crossref","unstructured":"Rui Y, Wilson DR, Green JJ. Non-Viral Delivery To Enable Genome Editing. Trends Biotechnol 2019; 37(3):281\u201393.","DOI":"10.1016\/j.tibtech.2018.08.010"},{"issue":"6405","key":"10.1007\/s13311-019-00712-9_bib82","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1126\/science.aat5011","article-title":"CRISPR-Cas guides the future of genetic engineering","volume":"361","author":"Knott","year":"2018","journal-title":"Science"},{"issue":"20","key":"10.1007\/s13311-019-00712-9_bib83","first-page":"4566","article-title":"Permanent inactivation of Huntington's disease mutation by personalized allele-specific CRISPR\/Cas9","volume":"25","author":"Shin","year":"2016","journal-title":"Hum Mol Genet"},{"issue":"7","key":"10.1007\/s13311-019-00712-9_bib84","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1172\/JCI92087","article-title":"CRISPR\/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of Huntington's disease","volume":"127","author":"Yang","year":"2017","journal-title":"J Clin Invest"},{"key":"10.1007\/s13311-019-00712-9_bib85","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3389\/fnins.2018.00075","article-title":"Precise Excision of the CAG Tract from the Huntingtin Gene by Cas9 Nickases","volume":"12","author":"Dabrowska","year":"2018","journal-title":"Front Neurosci"},{"issue":"2","key":"10.1007\/s13311-019-00712-9_bib86","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.celrep.2015.08.084","article-title":"Reversion of FMR1 Methylation and Silencing by Editing the Triplet Repeats in Fragile X iPSC-Derived Neurons","volume":"13","author":"Park","year":"2015","journal-title":"Cell Rep"},{"issue":"5","key":"10.1007\/s13311-019-00712-9_bib87","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/gt.2016.89","article-title":"Deletion of the GAA repeats from the human frataxin gene using the CRISPR-Cas9 system in YG8R-derived cells and mouse models of Friedreich ataxia","volume":"24","author":"Ouellet","year":"2017","journal-title":"Gene Ther"},{"issue":"1","key":"10.1007\/s13311-019-00712-9_bib88","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.scr.2015.12.031","article-title":"Generation of an isogenic, gene-corrected control cell line of the spinocerebellar ataxia type 2 patient-derived iPSC line H196","volume":"16","author":"Marthaler","year":"2016","journal-title":"Stem Cell Res"},{"issue":"11","key":"10.1007\/s13311-019-00712-9_bib89","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1089\/scd.2017.0209","article-title":"CRISPR\/Cas9-Targeted Deletion of Polyglutamine in Spinocerebellar Ataxia Type 3-Derived Induced Pluripotent Stem Cells","volume":"27","author":"Ouyang","year":"2018","journal-title":"Stem Cells Dev"},{"issue":"3","key":"10.1007\/s13311-019-00712-9_bib90","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.molcel.2017.09.033","article-title":"Impeding Transcription of Expanded Microsatellite Repeats by Deactivated Cas9","volume":"68","author":"Pinto","year":"2017","journal-title":"Mol Cell"},{"issue":"38","key":"10.1007\/s13311-019-00712-9_bib91","doi-asserted-by":"crossref","first-page":"9351","DOI":"10.1073\/pnas.1810062115","article-title":"Nucleosomes inhibit target cleavage by CRISPR-Cas9 in vivo","volume":"115","author":"Yarrington","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1007\/s13311-019-00712-9_bib92","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.cell.2017.07.010","article-title":"Elimination of Toxic Microsatellite Repeat Expansion RNA by RNA-Targeting Cas9","volume":"170","author":"Batra","year":"2017","journal-title":"Cell."},{"issue":"4","key":"10.1007\/s13311-019-00712-9_bib93","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1042\/BST20140049","article-title":"Mechanisms of transcriptional dysregulation in repeat expansion disorders","volume":"42","author":"Groh","year":"2014","journal-title":"Biochem Soc Trans"},{"issue":"4","key":"10.1007\/s13311-019-00712-9_bib94","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/emmm.201000064","article-title":"Long intronic GAA repeats causing Friedreich ataxia impede transcription elongation","volume":"2","author":"Punga","year":"2010","journal-title":"EMBO Mol Med"},{"issue":"19","key":"10.1007\/s13311-019-00712-9_bib95","doi-asserted-by":"crossref","first-page":"8366","DOI":"10.1093\/nar\/gkr542","article-title":"Hyperexpansion of GAA repeats affects post-initiation steps of FXN transcription in Friedreich's ataxia","volume":"39","author":"Kim","year":"2011","journal-title":"Nucleic Acids Res"},{"key":"10.1007\/s13311-019-00712-9_bib96","doi-asserted-by":"crossref","first-page":"20019","DOI":"10.1038\/srep20019","article-title":"Intrathecal delivery of frataxin mRNA encapsulated in lipid nanoparticles to dorsal root ganglia as a potential therapeutic for Friedreich's ataxia","volume":"6","author":"Nabhan","year":"2016","journal-title":"Sci Rep"},{"key":"10.1007\/s13311-019-00712-9_bib97","doi-asserted-by":"crossref","first-page":"10606","DOI":"10.1038\/ncomms10606","article-title":"Activating frataxin expression by repeat-targeted nucleic acids","volume":"7","author":"Li","year":"2016","journal-title":"Nat Commun"},{"issue":"1","key":"10.1007\/s13311-019-00712-9_bib98","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1089\/nat.2017.0703","article-title":"Activation of Frataxin Protein Expression by Antisense Oligonucleotides Targeting the Mutant Expanded Repeat","volume":"28","author":"Li","year":"2018","journal-title":"Nucleic Acid Ther"},{"issue":"16","key":"10.1007\/s13311-019-00712-9_bib99","doi-asserted-by":"crossref","first-page":"5351","DOI":"10.1093\/nar\/gkm589","article-title":"A persistent RNA.DNA hybrid formed by transcription of the Friedreich ataxia triplet repeat in live bacteria, and by T7 RNAP in vitro","volume":"35","author":"Grabczyk","year":"2007","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"10.1007\/s13311-019-00712-9_bib100","doi-asserted-by":"crossref","first-page":"e1004318","DOI":"10.1371\/journal.pgen.1004318","article-title":"R-loops associated with triplet repeat expansions promote gene silencing in Friedreich ataxia and fragile X syndrome","volume":"10","author":"Groh","year":"2014","journal-title":"PLoS Genet"},{"issue":"4","key":"10.1007\/s13311-019-00712-9_bib101","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1021\/cb400875u","article-title":"Targeting the r(CGG) repeats that cause FXTAS with modularly assembled small molecules and oligonucleotides","volume":"9","author":"Tran","year":"2014","journal-title":"ACS Chem Biol"},{"issue":"12","key":"10.1007\/s13311-019-00712-9_bib102","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/nrg3594","article-title":"Gene regulation by antisense transcription","volume":"14","author":"Pelechano","year":"2013","journal-title":"Nat Rev Genet"},{"issue":"5740","key":"10.1007\/s13311-019-00712-9_bib103","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1126\/science.1112009","article-title":"Antisense transcription in the mammalian transcriptome","volume":"309","author":"Katayama","year":"2005","journal-title":"Science"},{"issue":"6","key":"10.1007\/s13311-019-00712-9_bib104","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.cell.2010.11.020","article-title":"Comprehensive polyadenylation site maps in yeast and human reveal pervasive alternative polyadenylation","volume":"143","author":"Ozsolak","year":"2010","journal-title":"Cell"},{"issue":"3","key":"10.1007\/s13311-019-00712-9_bib105","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.molcel.2005.09.002","article-title":"Antisense transcription and heterochromatin at the DM1 CTG repeats are constrained by CTCF","volume":"20","author":"Cho","year":"2005","journal-title":"Mol Cell"},{"issue":"11","key":"10.1007\/s13311-019-00712-9_bib106","doi-asserted-by":"crossref","first-page":"e7914","DOI":"10.1371\/journal.pone.0007914","article-title":"Epigenetic silencing in Friedreich ataxia is associated with depletion of CTCF (CCCTC-binding factor) and antisense transcription","volume":"4","author":"De Biase","year":"2009","journal-title":"PLoS One"},{"issue":"17","key":"10.1007\/s13311-019-00712-9_bib107","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1093\/hmg\/ddr263","article-title":"A natural antisense transcript at the Huntington's disease repeat locus regulates HTT expression","volume":"20","author":"Chung","year":"2011","journal-title":"Hum Mol Genet"},{"issue":"4","key":"10.1007\/s13311-019-00712-9_bib108","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/ana.24761","article-title":"ATXN2-AS, a gene antisense to ATXN2, is associated with spinocerebellar ataxia type 2 and amyotrophic lateral sclerosis","volume":"80","author":"Li","year":"2016","journal-title":"Ann Neurol"},{"issue":"91","key":"10.1007\/s13311-019-00712-9_bib109","first-page":"25","article-title":"Beyond loss of frataxin: the complex molecular pathology of Friedreich ataxia","volume":"17","author":"Evans-Galea","year":"2014","journal-title":"Discov Med"},{"issue":"1","key":"10.1007\/s13311-019-00712-9_bib110","doi-asserted-by":"crossref","first-page":"17217","DOI":"10.1038\/s41598-018-35639-2","article-title":"FAST-1 antisense RNA epigenetically alters FXN expression","volume":"8","author":"Mikaeili","year":"2018","journal-title":"Sci Rep"},{"issue":"9","key":"10.1007\/s13311-019-00712-9_bib111","doi-asserted-by":"crossref","first-page":"5153","DOI":"10.1093\/nar\/gkx111","article-title":"CTG repeat-targeting oligonucleotides for down-regulating Huntingtin expression","volume":"45","author":"Zaghloul","year":"2017","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"10.1007\/s13311-019-00712-9_bib112","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/0092-8674(95)90074-8","article-title":"Trinucleotide repeats that expand in human disease form hairpin structures in vitro","volume":"81","author":"Gacy","year":"1995","journal-title":"Cell."},{"issue":"1","key":"10.1007\/s13311-019-00712-9_bib113","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.bpj.2017.05.041","article-title":"Structure and Dynamics of DNA and RNA Double Helices of CAG and GAC Trinucleotide Repeats","volume":"113","author":"Pan","year":"2017","journal-title":"Biophys J"},{"issue":"16","key":"10.1007\/s13311-019-00712-9_bib114","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.1021\/acs.jpcb.8b01658","article-title":"Structure and Dynamics of DNA and RNA Double Helices Obtained from the CCG and GGC Trinucleotide Repeats","volume":"122","author":"Pan","year":"2018","journal-title":"J Phys Chem B"},{"issue":"2","key":"10.1007\/s13311-019-00712-9_bib115","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1093\/nar\/gkx1186","article-title":"E-motif formed by extrahelical cytosine bases in DNA homoduplexes of trinucleotide and hexanucleotide repeats","volume":"46","author":"Pan","year":"2018","journal-title":"Nucleic Acids Res"},{"issue":"26","key":"10.1007\/s13311-019-00712-9_bib116","doi-asserted-by":"crossref","first-page":"9426","DOI":"10.1021\/bi980157s","article-title":"Influence of hairpins on template reannealing at trinucleotide repeat duplexes: a model for slipped DNA","volume":"37","author":"Gacy","year":"1998","journal-title":"Biochemistry"},{"issue":"6174","key":"10.1007\/s13311-019-00712-9_bib117","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1126\/science.1245831","article-title":"Promoter-bound trinucleotide repeat mRNA drives epigenetic silencing in fragile X syndrome","volume":"343","author":"Colak","year":"2014","journal-title":"Science"},{"issue":"1","key":"10.1007\/s13311-019-00712-9_bib118","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.cell.2018.08.005","article-title":"Disease-Associated Short Tandem Repeats Co-localize with Chromatin Domain Boundaries","volume":"175","author":"Sun","year":"2018","journal-title":"Cell"},{"issue":"5","key":"10.1007\/s13311-019-00712-9_bib119","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.cell.2018.06.044","article-title":"RNA-Dependent Epigenetic Silencing Directs Transcriptional Downregulation Caused by Intronic Repeat Expansions","volume":"174","author":"Eimer","year":"2018","journal-title":"Cell."},{"issue":"11","key":"10.1007\/s13311-019-00712-9_bib120","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/nrg2828","article-title":"Mechanisms of trinucleotide repeat instability during human development","volume":"11","author":"McMurray","year":"2010","journal-title":"Nat Rev Genet"},{"issue":"12","key":"10.1007\/s13311-019-00712-9_bib121","doi-asserted-by":"crossref","first-page":"e0189990","DOI":"10.1371\/journal.pone.0189990","article-title":"Somatic instability of the expanded GAA repeats in Friedreich's ataxia","volume":"12","author":"Long","year":"2017","journal-title":"PLoS One"},{"key":"10.1007\/s13311-019-00712-9_bib122","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1146\/annurev.bb.23.060194.002545","article-title":"H-DNA and related structures","volume":"23","author":"Mirkin","year":"1994","journal-title":"Annu Rev Biophys Biomol Struct"},{"issue":"45","key":"10.1007\/s13311-019-00712-9_bib123","doi-asserted-by":"crossref","first-page":"37366","DOI":"10.1074\/jbc.M508065200","article-title":"Increased negative superhelical density in vivo enhances the genetic instability of triplet repeat sequences","volume":"280","author":"Napierala","year":"2005","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1007\/s13311-019-00712-9_bib124","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.molcel.2012.08.002","article-title":"Genome-wide screen identifies pathways that govern GAA\/TTC repeat fragility and expansions in dividing and nondividing yeast cells","volume":"48","author":"Zhang","year":"2012","journal-title":"Mol Cell"},{"issue":"3","key":"10.1007\/s13311-019-00712-9_bib125","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.cell.2015.07.003","article-title":"Identification of Genetic Factors that Modify Clinical Onset of Huntington's Disease","volume":"162","author":"Genetic Modifiers of Huntington's Disease C","year":"2015","journal-title":"Cell"},{"issue":"R2","key":"10.1007\/s13311-019-00712-9_bib126","doi-asserted-by":"crossref","first-page":"R83","DOI":"10.1093\/hmg\/ddx261","article-title":"Genetic modifiers of Mendelian disease: Huntington's disease and the trinucleotide repeat disorders","volume":"26","author":"Holmans","year":"2017","journal-title":"Hum Mol Genet"},{"issue":"4","key":"10.1007\/s13311-019-00712-9_bib127","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.dnarep.2008.01.009","article-title":"Mrc1, Tof1 and Csm3 inhibit CAG.CTG repeat instability by at least two mechanisms","volume":"7","author":"Razidlo","year":"2008","journal-title":"DNA Repair (Amst)"},{"issue":"3","key":"10.1007\/s13311-019-00712-9_bib128","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S0959-440X(03)00081-2","article-title":"Recognition of the DNA minor groove by pyrrole-imidazole polyamides","volume":"13","author":"Dervan","year":"2003","journal-title":"Curr Opin Struct Biol"},{"issue":"31","key":"10.1007\/s13311-019-00712-9_bib129","doi-asserted-by":"crossref","first-page":"11497","DOI":"10.1073\/pnas.0604939103","article-title":"DNA sequence-specific polyamides alleviate transcription inhibition associated with long GAA.TTC repeats in Friedreich's ataxia","volume":"103","author":"Burnett","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1007\/s13311-019-00712-9_bib130","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S1097-2765(00)00100-3","article-title":"Specific gain- and loss-of-function phenotypes induced by satellite-specific DNA-binding drugs fed to Drosophila melanogaster","volume":"6","author":"Janssen","year":"2000","journal-title":"Mol Cell"},{"issue":"5","key":"10.1007\/s13311-019-00712-9_bib131","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.celrep.2016.06.075","article-title":"Stalled DNA Replication Forks at the Endogenous GAA Repeats Drive Repeat Expansion in Friedreich's Ataxia Cells","volume":"16","author":"Gerhardt","year":"2016","journal-title":"Cell Rep"},{"issue":"16","key":"10.1007\/s13311-019-00712-9_bib132","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1002\/cbic.200900263","article-title":"Structure-specific recognition of Friedreich's ataxia (GAA)n repeats by benzoquinoquinoxaline derivatives","volume":"10","author":"Bergquist","year":"2009","journal-title":"Chembiochem"},{"issue":"3","key":"10.1007\/s13311-019-00712-9_bib133","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1093\/nar\/gkh274","article-title":"Length-dependent structure formation in Friedreich ataxia (GAA)n*(TTC)n repeats at neutral pH","volume":"32","author":"Potaman","year":"2004","journal-title":"Nucleic Acids Res"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-019-00712-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13311-019-00712-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923018743?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923018743?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-019-00712-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:13:09Z","timestamp":1761808389000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923018743"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":133,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S1878747923018743"],"URL":"https:\/\/doi.org\/10.1007\/s13311-019-00712-9","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted Oligonucleotides for Treating Neurodegenerative Tandem Repeat Diseases","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-019-00712-9","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2019 The authors. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}